FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive, HER2-negative Advanced Breast Cancer By Ogkologos - November 20, 2024 591 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the INAVO120 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer MOST POPULAR Chaunté Lowe Has Competed In 4 Olympic Games, And Isn’t Letting... April 10, 2020 How Finding the Right Primary Care Physician During Cancer Has Helped... March 24, 2021 Maintenance Therapy Delays Cancer Growth for People With Advanced or Recurrent... July 24, 2023 FDA Approves New Initial Treatment Option for Some Metastatic Prostate Cancers August 4, 2023 Load more HOT NEWS Should People Over Age 75 Be Screened for Colorectal Cancer? Cancer Control in American Indian and Alaska Native Populations: A Conversation... COVID-19: “We’re having to rebuild and adapt because of coronavirus” NCI and FDA Address Common Concerns: A Win–Win for Making Progress...
